Clinical trials: QT Prolongation
- Condition QT Prolongation
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
ECG, Pharmacokinetics
Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML
This is a single-arm, open-label, Phase 4 study evaluating the effect of GO on the QTc, pharmacokinetics, safety, and immunogenicity of GO as a single-agent monotherapy in adult and pediatric patients with relapsed or refractory…
- Conditions
- ECG, Pharmacokinetics, Safety
- Trial name
- NCT03727750
- Testing
- Gemtuzumab Ozogamicin
- Where
- 24 sites in United States, Canada and 4 more
- Volunteers
- 51 people
- Sponsor
- Pfizer
Advanced Solid Tumor
QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors
The purpose of this study is to assess whether eribulin mesylate (E7389) has an impact on the electrocardiogram (ECG) with focus on cardiac repolarization, as measured by QT/QTc interval as well as through a…
- Trial name
- NCT01106248
- Testing
- Eribulin Mesylate
- Where
- 2 sites in France
- Volunteers
- 26 people
- Sponsor
- Eisai Limited
Long QT Syndrome (LQTS) 2
Evaluation of the Efficacy and Safety of THRV-1268 in Participants With Long QT Syndrome Type 2 (LQTS2) and Type 3 (LQTS3)
The goal of this clinical trial is to learn whether the study drug THRV-1268 can safely and effectively shorten the QT interval in people diagnosed with Long QT Syndrome Type 2 (LQTS 2) and Long QT Syndrome Type 3 (LQTS 3).
- Trial name
- Wave II (NCT07277582)
- Testing
- baseline lead-in, THRV-1268
- Where
- 9 sites in United States
- Volunteers
- 84 people
- Sponsor
- Thryv Therapeutics, Inc.